Summary:

Alembic Pharmaceuticals Limited has expanded its oncology and specialty portfolio with the USFDA's final approval of its generic methotrexate injection. Key strengths such as 50 mg/2 ml multi-dose vials and 1 g/40 ml single-dose vials are covered by the approval for an Abbreviated New Drug Application (ANDA). It can be marketed in the United States, a significant international pharmaceutical market, since it is therapeutically identical to Hospira's reference listed medication. Methotrexate injections are used to treat autoimmune diseases such rheumatoid arthritis, juvenile idiopathic arthritis, and severe psoriasis, as well as tumors like acute lymphoblastic leukemia, osteosarcoma, and breast cancer. Alembic's US generic presence is strengthened by the approval, which also encourages growth in difficult injectables and high-value cancer treatments. The company is expanding its pipeline and global presence with regulatory clearances.

Source: IBEF

Disclaimer: The information on this website comes from the India Brand Equity Foundation (IBEF), a reliable source for thorough insights into numerous areas of the Indian economy. While we aim to offer accurate and up-to-date information, the views, opinions, and analyses stated herein are solely those of the authors and contributors and do not necessarily represent IBEF's official stance or position. Readers should check information from credible sources and use their own discretion when relying on content provided on this site. We assume no responsibility or liability for the supplied content, including its accuracy, completeness, and usefulness.